Informa
TIDES USA: Oligonucleotide & Peptide Therapeutics
2025年5月19-22日
美國加州聖地牙哥, Manchester Grand Hyatt San Diego
TIDES USA: Oligonucleotide & Peptide Therapeutics 2025
日期:2025年5月19-22日
地點:美國加州聖地牙哥, Manchester Grand Hyatt San Diego

TIDES USA:連結研究與現實世界

讓先驅者交流想法和加速藥物上市的平台

TIDES USA 是北美透過合作發現、開發和商業化,加速寡核苷酸及寡核苷酸創新的首要論壇。產業領導者將在此探討寡核苷酸、寡核苷酸、mRNA 和基因組編輯的最先進的策略,以促成新藥從研發階段邁向市場。

寡核苷酸 • 胜肽 • mRNA • 基因組編輯 • 遞送

Choose your language
Chinese
Japanese
Korean
English

TIDES USA的相關數據

1900+

Attendees

150+

Industry Speakers

170+

Sponsors

8

Workshops

5

Tracks

為什麼要參加 TIDES USA 2025:通往科學創新與合作的大門

跨產業創新交流

可與來自不同領域的專家互動交流並分享見解。參與豐富的討論,激發創新想法,挑戰傳統思維,參與有助於醫療開發突破的深度討論。

專業科學內容

可直接接觸傑出的科學家,透過與他們密切的互動,得到改進研究方法和克服技術障礙所需的獨特機會。

展示研究成果的機會

可透過海報發表計畫,展示您最新的科學突破,並提高研究曝光度。您的研究成果將於實體展區及 ConnectMe 數位平台上展示,最大化提升您與潛在合作伙伴的合作機會。

尖端技術展示

可在綜合展示廳內,親身體驗最新的技術創新,探索將徹底改變研發流程的尖端工具和解決方案。

生命科學烏托邦:聖地牙哥

聖地牙哥擁有超過 1,200 家生物技術公司,全年氣候宜人,是一個充滿活力的生命科學中心,為科學合作和交流提供了充滿活力的環境。

強化的數位會議體驗

可透過具備議程、參與者清單、匹配和無縫調度工具的ConnectMe 應用程式,最大限度地提升您的會議體驗。藉由即時更新,可以透過整合的數位平台有效地管理您與他人的交際互動機會。

TIDES 將分享寡核苷酸、胜肽、mRNA、基因組編輯和藥物傳遞方面的專業知識

透過 TIDES USA,您可以創建自己的議程以獲得獨特的、客製化的見解。六個同時舉的分會上有超過 200 場演講供您選擇。

寡核苷酸 CMC(化學、製造和品質控制)

• 最佳化 CMC 策略,加速開發

• 掌握最新分析技術與品質管控(QC)

• 簡化監管流程,加速市場化

• 擴大可靠的製造能力

寡核苷酸發現、臨床前及臨床

• 設計具突破性的藥物特性

• 快速篩選候選藥物

• 最佳化臨床試驗設計

• 與業界領袖對標學習

胜肽CMC(化學、製造和品質控制)

• 最大提升產量與製程效率

• 應對複雜的監管要求

• 運用最新的 QC 技術

• 深入了解新興分子挑戰

胜肽發現、臨床前及臨床

• 先進的胜肽設計工程

• 創新的藥物傳輸系統

• 加速藥物發現管道

• 從成功的臨床案例中學習

mRNA 藥物/疫苗和基因組編輯

• mRNA 設計突破的先驅

• 掌握尖端傳輸技術

• 變革性的基因編輯技術

• 成功擴大生產

藥物傳輸技術創新(Drug Delivery)

• 開發標靶傳輸解決方案

• 創新口服胜肽傳輸技術

• 先進的設備型策略

• 最佳化高分子藥物傳輸

接獨潛在客戶!

關於贊助、參展及廣告機會,請洽詢環球資訊有限公司(Global Information Inc.)。

Mike Pennington, Ph.D.

Chief Scientific Officer

AmbioPharm, Inc.

With the current situation facing the world with the Covid-19 pandemic, we fully support the digital format that is being offered for the TIDES meeting(s). The digital format will still allow AmbioPharm to reach out to our existing as well as new potential clients. This is the right decision for all of us.

Jesper Lau, Ph.D.

VP, Protein and Peptide Chemistry

Novo Nordisk, Denmark

The yearly TIDES conferences are among the most important events within peptide and oligonucleotide discovery and development and it has always been among my high priority to be able to join them. I am thus delighted to learn that Informa Connect will deliver TIDES USA Boston 2020 in a virtual format, and I am convinced that a digital meeting will be extremely appreciated in order to continue the important global communication among the scientific communities during these tough times.

Bruce Morimoto, Ph.D.

Vice President, Drug Development-Operations

Alkahest, USA

TIDES USA has been my go-to meeting to learn about the latest trends and scientific developments in the peptide and oligonucleotide field. The global pandemic has challenged us to find alternative venues to obtain the critical content necessary for us to continue to push the boundaries of innovation. TIDES provides this platform by integrating research and discovery with development and manufacturing. The digital meeting format will surely provide the high-quality content I have come to expect from the TIDES conference series.

Mike Pennington, Ph.D.

Chief Scientific Officer

AmbioPharm, Inc.

With the current situation facing the world with the Covid-19 pandemic, we fully support the digital format that is being offered for the TIDES meeting(s). The digital format will still allow AmbioPharm to reach out to our existing as well as new potential clients. This is the right decision for all of us.

Jesper Lau, Ph.D.

VP, Protein and Peptide Chemistry

Novo Nordisk, Denmark

The yearly TIDES conferences are among the most important events within peptide and oligonucleotide discovery and development and it has always been among my high priority to be able to join them. I am thus delighted to learn that Informa Connect will deliver TIDES USA Boston 2020 in a virtual format, and I am convinced that a digital meeting will be extremely appreciated in order to continue the important global communication among the scientific communities during these tough times.

Bruce Morimoto, Ph.D.

Vice President, Drug Development-Operations

Alkahest, USA

TIDES USA has been my go-to meeting to learn about the latest trends and scientific developments in the peptide and oligonucleotide field. The global pandemic has challenged us to find alternative venues to obtain the critical content necessary for us to continue to push the boundaries of innovation. TIDES provides this platform by integrating research and discovery with development and manufacturing. The digital meeting format will surely provide the high-quality content I have come to expect from the TIDES conference series.

Mike Pennington, Ph.D.

Chief Scientific Officer

AmbioPharm, Inc.

With the current situation facing the world with the Covid-19 pandemic, we fully support the digital format that is being offered for the TIDES meeting(s). The digital format will still allow AmbioPharm to reach out to our existing as well as new potential clients. This is the right decision for all of us.